Connect with us

Micro Cap Insider

Red Days on Vision Industries Corp (OTCMKTS:VIICQ)

Published

on

Vision Industries Corp (OTCMKTS:VIICQ) made a big move up in January to highs well over a penny on significant volume but has been in steep decline since drifting into oblivion.

The last press release from VIICQ was in November of last year when they said they have received an official request from a Canadian Energy Solutions Company to prototype 32 Tyrano(TM) trucks at a remote mining site in Northern Canada. The mining site has a massive wind turbine facility which can produce hydrogen through an electrolyzer. With the capability to produce on-site hydrogen, the mining company hopes to eliminate the need for shipping large quantities of diesel fuel (to the remote site) before onset of winter. During the winter season, the shipping lanes are usually frozen.

VIICQ is an exciting story that is quickly developing; they are the maker of the Tyrano; the nation’s first street-legal zero emission Class 8 hydrogen/electric hybrid truck filed for Chapter 11 bankruptcy protection on September 25. This was caused by the Company’s inability to obtain quorum at its August 22, 2014, Shareholder Meeting, at which the Company sought permission to increase its authorized share count from 500 million to 10 billion common shares.

Vision Industries Corp (OTCMKTS:VIICQ) products include: (1) the Tyrano, a hydrogen/electric hybrid Class 8 truck; and (2) the Zero Emission Terminal Tractor (“Zero TT”), a hydrogen/electric hybrid terminal tractor. The Tyrano is the nation’s first street-legal zero emission Class 8 hydrogen/electric hybrid truck designed for local and regional drayage. The Zero TT is a zero emission, hydrogen/electric hybrid terminal tractor designed to work a double shift before refueling.

VIIC heavy-duty Class 8 trucks are substantially less expensive to operate on a per mile basis than diesel and natural gas powered trucks. The cost savings on a per mile basis versus diesel and natural gas, is expect to be around 35% to 45%. Debtor’s hydrogen/elect ric drive system offers almost double the pulling-power of a conventional diesel truck.

Vision Industries target markets are the: Trucking fleet operators; Warehouse operators; Shipping operators; and Rail yard operators in the Ports of Los Angeles and Long Beach, the largest port of entry system in the United States (with $304 billion of freight moved by 30,000 trucks per annum).

We have a Monster Pick Coming. Subscribe Right Now!

VIIC was awarded contracts by the Port of Long Beach to deliver a Tyrano and Zero TT for demonstration and drayage testing. The Company currently operates out of a 21,087 ft.² warehouse and office facility located at 2230 East Artesia Blvd., Long Beach, CA 90805.

Back in 2009 the excitement on Vision was palpable. Investors described the Company as ‘operating on the cutting edge of emission free pollution for both trucks and cars. The electric and hydrogen fuel cell technology is green green green. ‘ Then-Governor of California, Arnold Schwarzenegger touted the company’s zero-emission semi-tractor trailer outside the California State Capitol commenting at the time “This is very exciting, this truck that is behind me here,”

At the event to promote the Tyrano was VIIC CEO Martin Schuermann, a colorful guy that used to work as a film producer and distributor. He worked for the company that produced films like Basic Instinct 2, Terminator 3, RV, Alexander. He gained more fame when he was featured on Celebrity Wife Swap with his wife former MTV VJ Downtown Julie Brown.

Over the years Vision fell into trouble due to continued significant operating expenses and lack of any profits culminating in the bankruptcy filing back on September 21.

Conclusion: VIIC has experienced a hard fall in recent months as the Company was forced to file for bankruptcy protection back in September and saw their stock land way down in the subs. Even before the bankruptcy VIIC was trading as low as a penny, a far cry indeed from the prices over $1 the stock commanded several years ago with $100 million plus market valuation.

According to the last filing from VIIC the SC 13G from Oct 2, 2014 the Company currently has 355,345,942 shares outstanding. This puts VIICQ at a total market valuation of $1,066,037 at current price levels. Some might consider this absurdly undervalued.

We have all seen the incredible rise of many Q stocks after the bankruptcy, we can remember AAMRQ and the run it made from $0.40 to over $12 per shares or FnF which ran from pennies to over $6 per share.

Vision arguable represents an even more compelling situation here on the Qs found here. The filing states:

  1. Events Precipitating the Chapter 11 Case.

Debtor’s financial difficulties were primarily caused by a lack of operating capital. In the months leading up to the bankruptcy filing, Debtor’s principals sought permission from the largest debt and convertible note holders to increase Debtor’s authorized share count from 500 million to 10 billion common shares. The increase in authorized shares was requested by management to enable Debtor to seek further funding to continue operations. The request was not approved, which made it impossible for Debtor to raise capital to fund operations. Debtor anticipates that it will secure substantial post-petition DIP financing pursuant to ongoing negotiations with several potential investors. Once DIP financing is secured, Debtor will propose a plan of reorganization to restructure its debts and emerge from bankruptcy as a profitable entity.0

  1. Debtor’s Business Reorganization Effort

Debtor intends to secure post-petition DIP financing by the end of October 2014 to, at minimum, remain post-petition current on lease payments to its landlord, compensate court approved professionals associated with this Chapter 11 case, and obtain an order confirming Debtor’s Chapter 11 a plan of reorganization. It is anticipated that if a plan is confirmed, it will come as a result of a substantial loan or a capital infusion.[/b] Should Debtor be unable to obtain such financing, Debtor will consider selling its assets to pay creditors.

To Find out the inside Scoop on VIIC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Currently drifting into oblivion the chances that Vision emerges from Bankruptcy a profitable entity seem to be fading as the stock moves lower. The company’s truck the Tyrano is a green technology with cost savings on a per mile basis versus diesel and natural gas, expected to be around 35% to 45%. We will be updating on VIICQ on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with VIICQ.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VIICQ either long or short and we have not been compensated for this article.

Featured

IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment

Published

on

On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European Society of Breast Imaging. Their cutting-edge ProSense® System, designed for minimally invasive cryoablation, is marketed and sold worldwide for its cleared indications in the U.S., Europe, and China. More recently they gained approvals in India, and Brazil and have additional distribution through MC Medical to continue expanding in Europe. More importantly, the latest independent study confirms that the technology is a safe & effective outpatient procedure for breast cancer, with 96.8% success rate.

More Background:

Their system has the potential to revolutionize cancer treatment not only for breast cancer, but also for kidney, bone, and lung cancers. To date, the system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

During the event, Dr. Lucía Graña-López, a radiologist specializing in breast and women’s imaging, led an independent study. The study explored cryoablation as a viable alternative to surgery for early-stage breast cancer in patients who preferred a non-surgical route. The results were promising, suggesting that cryoablation could be a successful treatment option, particularly for patients hesitant about traditional surgery.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Clinical Study:

The study involved 31 patients with early-stage breast cancer who opted out of surgery, and the outcomes showed that cryoablation was well-tolerated with no major complications. This alternative approach could potentially be a game-changer, especially for breast cancer, which is one of the most prevalent cancers globally. Many patients, particularly older individuals, are seeking less invasive alternatives to surgery, making cryoablation an appealing option.

Dr. Graña-López envisions cryoablation becoming a significant alternative to surgery, particularly for early-stage breast cancer in post-menopausal women. Moreover she believes this technology could reshape how we approach treatment in other indications, particularly for kidney, lung, and thyroid gland cancers.

These results from this independent study are are in line with the ongoing ICE3 study, the largest of its kind in the U.S., set to conclude in early 2024.

We will update you on ICCM when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by marijana1 from Pixabay

Continue Reading

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.